What question did this study set out to answer?

This analysis aims to evaluate the safety and antitumor activity of a specific chemotherapy regimen in patients with EGFR-mutated advanced NSCLC who previously discontinued osimertinib.

March 21, 2026ESMO Open0 citationsOpen Access

27P Chemotherapy (chemo) rechallenge in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC who discontinued 1L osimertinib (osi) + platinum–pemetrexed (plat–pem) due to progression (PD): FLAURA2 exploratory analysis

CEC. Escriu PJP.A. Jänne DPD. Planchard

Key Points

This analysis aims to evaluate the safety and antitumor activity of a specific chemotherapy regimen in patients with EGFR-mutated advanced NSCLC who previously discontinued osimertinib.
Analyzed adverse events associated with chemotherapy rechallenge.
Compared safety profiles of aumolertinib and etoposide.
Assessed antitumor activity in treatment-naive EGFR-mutated NSCLC.
Reported adverse events included anemia (18.3%), urinary tract infection (11.7%), and decreased neutrophil count (10%).
No new safety signals were identified compared to existing drug profiles.
The combination of aumolertinib and etoposide showed promising antitumor activity.

Abstract

adverse events (AEs) of any grade were anemia (18.3%), urinary tract infection (11.7%), and decreased neutrophil count (10.0%).No new safety signals were identified compared with the established profiles of each individual drug. Conclusions:The all-oral combination of aumolertinib and etoposide demonstrated promising antitumor activity and a manageable safety profile in treatment-naive EGFR-mutated NSCLC.This regimen offers a potential convenient, outpatient-based therapeutic strategy worthy of further validation.Clinical trial identification: NCT06463171.

KI fragen

Bookmark

View Full Paper

Cite This Study

Escriu et al. (Tue,) studied this question.

synapsesocial.com/papers/69be34886e48c4981c672c53 https://doi.org/https://doi.org/10.1016/j.esmoop.2026.106334

KI fragen

Bookmark

View Full Paper